• Age 18 to 55 years, inclusive.

• Body mass index (BMI) ≥18.0 kg/m2 and ≤ 32.0 kg/m2.

• Participants are in good general health as determined by the investigator, based on a medical evaluation including medical history, vital signs, physical examination, 12-lead electrocardiogram, clinical laboratory tests.

• Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as hysterectomy, bilateral ovariectomy or post-menopause. A postmenopausal state should be confirmed by at least 12 months since last menstrual period and FSH \> 40 IU.

• Women of childbearing potential (WOCBP) may be enrolled in the study if the participant:

‣ has practiced highly-effective contraception for 28 days prior to first injection, and

⁃ has a negative pregnancy test at Screening, and

⁃ agrees to refrain from ova donation from Screening until 48 weeks after completion of the final injection, and

⁃ practices abstinence as part of her usual and preferred lifestyle, and

⁃ has agreed to continue highly-effective contraception from Screening until 48 weeks after completion of the final injection.

• Male participants:

‣ with documented bilateral orchiectomy, or

⁃ agrees to practice abstinence from penile-vaginal intercourse or use condoms from Screening until 48 weeks after completion of the final subcutaneous injection, and

⁃ agrees to refrain from sperm donation from Screening until 48 weeks after completion of the final injection, and

⁃ the highly effective contraceptive methods listed above should also apply to WOCBP partners of male participants for the specified duration, in addition to male condom use, from Screening until 48 weeks after completion of the final injection.

• Willing to comply with the study requirements and to provide written informed consent.